On Demand 2023 Monday General Sessions

This course includes the following sessions from Monday's program:

  • Plenary - Don't Be Scared of the Skin: Practical Pearls to Treat Urticaria and Atopic Dermatitis
  • Evolutions in Anaphylaxis
  • Inborn Errors of Immunity - Insights From the Practice Parameter Update
  • WAO - World Allergy Forum - Allergen Immunotherapy Update
  • Drug Allergy in Evolving Patient Care
  • Supplements, Immune Boosting, Special Diets & Cannabis: What Every Allergist Needs to Know
  • AACA: Updates from the Allergen Immunotherapy Primer

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 9.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify if patients with chronic urticaria need any laboratory work-up for diagnostic purposes or therapeutic response.
  • Summarize available data on various therapies beyond H1-antihistamines for the treatment of chronic urticaria.
  • Compare recommendations for the management of atopic dermatitis.
  • Discuss how the field of primary immune deficiency or inborn errors of immunity is evolving.
  • Develop a diagnostic work-up for patients presenting with possible inborn errors of immunity.
  • Identify novel treatment strategies for a broad array of patients with inborn errors of immunity.
  • Recognize alpha-gal syndrome in children as an explanation for cases of anaphylaxis and urticaria in Lone Star tick endemic areas.
  • Understand the diagnosis of anaphylaxis, the grading of anaphylaxis symptoms, and the utilization of current and emerging biomarkers in anaphylaxis based on current clinical guidelines.
  • Recognize patients with HaT and MC disorders are at increased risk of anaphylaxis.
  • Demonstrate the use of current and future biologics in the prevention of anaphylaxis.
  • Explain the importance of the molecular composition of the allergen extracts used in allergen immunotherapy.
  • Differentiate the different types of allergen extracts available for immunotherapy.
  • Clearly identify the mechanisms responsible for the beneficial effects of AIT using modified extracts, including ultra-rush updosing schemes.
  • Identify the need for maintaining drug allergy de-labeling.
  • Recognize the potential for telemedicine in drug allergy diagnosis and management.
  • Evaluate the candidates and tools of drug desensitization.
  • Analyze advantages and disadvantages of SLIT use in pediatric populations.
  • Leverage rush and cluster immunotherapy with appropriate patients.
  • Engage patients in successful shared decision-making processes.
  • Understand how OMT manipulation practices are being used in patients with allergic disease and the evidence behind these practices. 
  • Review the safety considerations for natural products commonly used by patients with allergic disease.
  • List the potential allergic consequences of using cannabis treatment and the evidence of cannabis use in different allergic conditions if any.
  • Help their patients navigate pre, pro and post biotics and other diet practices.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 9.25 AMA PRA Category 1 Credit™
  • 9.25 Attendance
  • 9.25 CBRN
Course opens: 
12/01/2023
Course expires: 
11/30/2026
Part of: 
On Demand ACAAI 2023 Annual Scientific Meeting General Sessions
Rating: 
0

Jay A. Lieberman, MD, FACAAI  
Jonathan A. Bernstein, MD, FACAAI  
Marc A. Riedl, MD, MS  
Mark Boguniewicz, MD, FACAAI
Desiree E. Larenas-Linnemann, MD, FACAAI  
Ari Heffes-Doon, MD  
Jonathan Lyons, MD  
Paul Turner, PhD
Kathleen R. May, MD, FACAAI  
Bryan L. Martin, DO, FACAAI  
Ignacio J. Ansotegui, MD, PhD  
Sandra N. Gonzalez-Diaz, MD, PhD, FACAAI  
Mário Morais-Almeida, MD
Caroline C. Horner, MD  
Jordan S. Orange, MD, PhD, FACAAI  
Javier Chinen, MD, PhD  
Jennifer R. Heimall, MD, FACAAI
Sandra M. Gawchik, DO, FACAAI  
Russell A. Settipane, MD, FACAAI  
Michael S. Blaiss, MD, FACAAI  
Justin C. Greiwe, MD, FACAAI  
Don A. Bukstein, MD, FACAAI  
Lawrence M. DuBuske, MD, FACAAI
Payel Gupta, MD, FACAAI  
Anil Patel, MD, FACAAI  
Dipa K. Sheth, MD, FACAAI, FAAAAI  
Gary K. Soffer, MD 
Anil Nanda, MD, FACAAI  
Atoosa Kourosh, MD, MPH, FACAAI
William K. Dolen, MD, EF  
Fernanda D. Young, MD 
Allison C. Ramsey, MD, FACAAI  
Rebecca R. Saff, MD, PhD  
Mariana C. Castells, MD, PhD, FACAAI  
John M. Kelso, MD, FACAAI

Available Credit

  • 9.25 AMA PRA Category 1 Credit™
  • 9.25 Attendance
  • 9.25 CBRN
Please login or create an account to take this course.